
Overview
Celon Pharma is an integrated pharmaceutical company conducting advanced scientific research and manufacturing modern medicines. The company also markets its own pharmaceutical products.
Financials
Revenue history (in m)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 127 days for 2024). All were audited by a statutory auditor.
- 202522/09/2026
- 202419/11/2025
- 202305/07/2024
- 202202/10/2023
- 202128/06/2022
- 202016/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 15.80
- High
- PLN 15.86
- Low
- PLN 15.20
- Volume
- 34.15K
- Avg. vol.
- 32.6K
- Market cap
- PLN 832.39M
- P/E ratio
- 7.53
- EPS
- PLN 2.05
- Shares outstanding
- 53.91M
- 52-week
- PLN 15.20 – 17.72
- Dividend yield
- 0.52%
- Dividend
- PLN 0.08
- Ex dividend date
- Jun 27, 2024
- ISIN
- PLCLNPH00015
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 16.23m | USD -2.56m | USD -8.26m |
| Q1 2026 | USD 16.71m | USD -1.61m | USD 43.92m |
| Q4 2025 | USD 16.16m | USD 634.61k | USD -6.25m |
| Q3 2025 | USD 18.60m | USD 2.02m | USD 919.89k |
Results for Q3 2026:Nov 18, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Websites
- zarixa.plZarixaWordPressGoogle AnalyticsGoogle Tag ManagerNginx
Trademarks
The company holds 22 active trademarks registered with the Polish Patent Office. 7 marks have expired or were not registered. The first mark was filed in 2002.
| Mark | Protected until | |
|---|---|---|
| REDUZEK (word) | Sep 12, 2034 | |
| Pixara (word) | Jan 19, 2034 | |
| Zarixa (word) | Jun 24, 2032 | |
| Rivaxa (word) | Jun 24, 2032 | |
| TIKOZEK (word) | Apr 17, 2030 |
Authorized Representatives
Manner of representation
President of the Management Board independently; two members of the management board jointly; one member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Action for Development of Research sp. z o.o. | 342,206.92 USD | 73.2813% |
Bank accounts
Registered as a VAT taxpayer on 2002-06-25.
74 2490 0005 0000 4600 3169 2874
48 1050 1025 1000 0090 8183 5200
87 2490 0005 0000 4600 6926 3359
Debt
No entries in the National Debtors Register (KRZ).
Public aid
57 public aid cases recorded, with a total value of $144,110,691.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 23, 2026 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Jun 22, 2026 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Jun 22, 2026 | Aid for research and development projects: fundamental research | –– | Prezes Agencji Badań Medycznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biofarm sp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o. | $102,266,019.67 | lekam.pl | ||
| Sandoz Polska sp. z o.o. | $89,136,265.74 | sandoz.com | ||
| Chiesi Poland sp. z o.o. | $87,762,158.97 | chiesi.com | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| Solinea sp. z o.o. | $72,245,607.27 | solinea.pl | ||
| SUN-Farm sp. z o.o. | $51,063,341.52 | sunfarm.pl | ||
| Wörwag Pharma Operations sp. z o.o. | $46,828,794.87 | woerwagpharma.pl | ||
| US Pharmacia sp. z o.o. | $41,267,631.19 | uspharmacia.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-10 | PKD change (Removed: 46.75.Z, 72.11.Z, 72.19; Added: 46.85.B, 72.10.Z) | |
| 2024-11-29 | Share capital increase (5,375,650.00 PLN → 5,385,650.00 PLN) | |
| 2024-08-06 | Share capital increase (5,105,650.00 PLN → 5,375,650.00 PLN) | |
| 2023-08-18 | Share capital increase (5,103,500.00 PLN → 5,105,650.00 PLN) | |
| 2022-10-17 | Share capital increase (5,103,000.00 PLN → 5,103,500.00 PLN) |
FAQ
Last updated: 2026-09-22